Recently, even though immunotherapies and gene mutation therapies that specifically targeted lung cancer have demonstrated excellent therapeutic effects, acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is unavoidable. This evidence concerns the gene EGFR and lung cancer.